Today: 19 May 2026
Coinbase stock slides after Nevada lawsuit over sports event contracts; earnings ahead
5 February 2026
2 mins read

Coinbase stock slides after Nevada lawsuit over sports event contracts; earnings ahead

New York, Feb 4, 2026, 19:06 EST — After-hours

  • After-hours trading saw Coinbase shares drop roughly 6% following a lawsuit from Nevada’s gaming regulator targeting sports-linked “event contracts.”
  • Coinbase slammed Nevada’s action as a “state power grab,” insisting that federal derivatives regulations should take precedence.
  • Traders are eyeing crypto prices alongside Coinbase’s February 12 earnings for signals on volumes and potential legal risks.

Shares of Coinbase Global dropped 6.2% to $168.62 in after-hours trading Wednesday, as losses deepened following Nevada’s gaming regulator’s move to block the company’s sports-linked event contracts.

Nevada’s move opens a fresh battle over “prediction markets,” a tool brokers and crypto platforms have touted to keep retail traders engaged. But states are cracking down, viewing sports-linked contracts more as gambling than financial products. SBC Americas

The legal blow came amid a drop in crypto prices and a slide in stocks tied to exchanges, raising questions about whether trading volume is fading ahead of Coinbase’s quarterly earnings.

The Nevada Gaming Control Board announced it filed a civil enforcement action in Carson City against Coinbase Financial Markets on Feb. 2, aiming to secure a court order to halt what it described as unlicensed wagering. “The Board takes seriously its obligation to operate a thriving gaming industry and to protect Nevada citizens,” chairman Mike Dreitzer said.

The dispute revolves around “event contracts” — derivatives that pay out depending on whether a specific real-world event occurs. Coinbase has been expanding beyond crypto trading, offering event contracts linked to outcomes as part of its bid to capture more retail trading activity. Reuters

Coinbase pushed back against Nevada’s action in a statement shared by PYMNTS. Ryan VanGrack, the company’s vice president of litigation, slammed it as a “state power grab” and a “manufactured emergency,” asserting that Congress granted the U.S. Commodity Futures Trading Commission sole authority over event contracts. PYMNTS.com

Nevada is seeking emergency relief from the court, pushing for a temporary restraining order and a preliminary injunction to stop contracts linked to sporting events, Cointelegraph reported.

Crypto markets dragged the mood. Bitcoin slipped 3.4%, hitting around $72,992, while ether dropped 3.8% to about $2,140. These declines often stoke worries over weaker spot trading volumes, putting exchange stocks under pressure.

Shares of other retail-trading firms followed suit. Robinhood Markets dropped 7.4%, while Strategy, which leans heavily on bitcoin, slid 3.2% in after-hours trading.

Dip-buying showed up on Tuesday as Cathie Wood’s ARK Invest picked up 3,510 shares of Coinbase, according to Investors.com’s daily trade count of ARK’s moves.

The risk remains that additional states could follow Nevada’s lead, or courts might side with state gambling regulations over federal derivatives rules. This could force Coinbase to withdraw or overhaul products it counts on for growth. A swift victory would help limit the damage, but an injunction could hit hard and fast in a critical test case.

Coinbase’s upcoming catalyst arrives Feb. 12, when the company will release its Q4 and full-year 2025 earnings after the market closes. A webcast is set for later that day.

Stock Market Today

  • Royal Bank of Canada Shares Show 25% Undervaluation Despite Strong Rally
    May 18, 2026, 9:50 PM EDT. Royal Bank of Canada (TSX:RY) has gained 47.9% over the past year, yet valuation analysis indicates it remains undervalued by 25.4%. The bank closed at C$252.50, with a healthy return on equity of 17.17%. Using an Excess Returns model that compares profits versus the cost of equity, analysts estimate an intrinsic value near C$338 per share, suggesting a significant margin for further gains. Despite strong recent performance and solid fundamentals, the stock scores just 2 out of 6 on Simply Wall St's valuation checks, reflecting mixed signals for investors. Ongoing scrutiny of balance sheet strength and regulatory capital alignment continues amid evolving market conditions for Canadian banks.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Uber stock sinks after earnings outlook miss as CFO change and robotaxi push hit focus
Previous Story

Uber stock sinks after earnings outlook miss as CFO change and robotaxi push hit focus

Qualcomm stock price jolts after-hours as QCOM flags memory crunch in outlook
Next Story

Qualcomm stock price jolts after-hours as QCOM flags memory crunch in outlook

Go toTop